Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Not every patient will benefit, and those who do will benefit in different ways depending on their diagnoses, BMI, and which program they qualify for
I began to ask simple questions about their menopausal journey, and the responses appeared to reveal a deeper connection between hormonal changes and musculoskeletal health than I had ever considered
This is particularly important with tirzepatide, which can reduce oral contraceptive exposure during initiation and dose escalation, potentially requiring backup contraception
This narrative review analyses the usefulness of acetyl-l-carnitine in the treatment of neuropathic pain
To understand how this evolving market might play out, this paper will address the following questions: What is the current state of the incretin mimetic market in diabetes and obesity, and how did we get here
GLP-1: New Metrics, New Molecules, New Prices Topics We Cover: 00:00 New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 A new oral triple agonist shows record-setting absorption rates 07:00 Fractal Healths Revita procedure: weight maintenance after stopping GLP-1s 12:00 Zepbound vial prices drop (full breakdown by dose) 16:00 Daves personal experience switching off Mounjaro and intense hunger return 22:00 Novo Nordisks EVOKE/EVOKE+ Alzheimers trial: what the data really means 29:00 Why GLP-1 neurological research is just getting started 33:00 Updates on access, partners, and major news coming soon for Medicare patients If youre on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor
